Holen Sie sich die Stockscreener-App
2.90
0.35%
0.010
Handel nachbörslich:
2.90
Orchestra Biomed Holdings Inc Aktie (OBIO) Neueste Nachrichten
Orchestra BioMed Reports Q1 2025 Financial Results and Advances Key Clinical Programs - MyChesCo
Orchestra BioMed Expands Patent Portfolio for AVIM Therapy, Gains FDA Breakthrough Designation - MSN
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Tops Revenue Estimates - MSN
Chardan Capital Maintains Buy Rating on OBIO with $20 Price Targ - GuruFocus
Barclays PLC Boosts Holdings in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) - Defense World
Wells Fargo & Company MN Buys 3,992 Shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) - Defense World
Orchestra BioMed HoldingsBreakthrough Device Designation Gives Speculative Optimism - Seeking Alpha
Chardan Capital Maintains Buy Rating on OBIO with $20 Price Target | OBIO Stock News - GuruFocus
Orchestra BioMed (OBIO) Surpasses Revenue Estimates with Strong Q1 Growth | OBIO Stock News - GuruFocus
Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy and IDE Approval for Virtue SAB Trial - Nasdaq
Orchestra BioMed Reports First Quarter 2025 Financial - GlobeNewswire
Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones - Stock Titan
4 No-Brainer Stocks to Buy Right Now - The Globe and Mail
(OBIO) On The My Stocks Page - news.stocktradersdaily.com
Orchestra BioMed receives FDA approval to initiate Virtue Trial - Med-Tech Insights
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Shares Sold by Price T Rowe Associates Inc. MD - The AM Reporter
RTW INVESTMENTS, LP Increases Stake in Orchestra BioMed Holdings Inc - GuruFocus
ORCHESTRA BIOMED Earnings Preview: Recent $OBIO Insider Trading, Hedge Fund Activity, and More - Nasdaq
Orchestra BioMed’s AVIM Therapy Global Intellectual - GlobeNewswire
Orchestra BioMed (OBIO) Expands Patent Portfolio for AVIM Therap - GuruFocus
Orchestra BioMed Expands Patent Portfolio with 10 New Patents for Hypertension Treatment, Totaling 120 Global Patents - Nasdaq
Orchestra BioMed’s AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure - GlobeNewswire
Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - MSN
BlackRock, Inc. Reduces Stake in Orchestra BioMed Holdings Inc. - GuruFocus
Orchestra BioMed (NASDAQ:OBIO) Price Target Lowered to $12.00 at Barclays - Defense World
Orchestra BioMed Holdings (OBIO) Target Price Adjustment by Barc - GuruFocus
Barclays Adjusts Price Target for Orchestra BioMed (OBIO) | OBIO Stock News - GuruFocus
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Shares Bought by JPMorgan Chase & Co. - Defense World
OBIO: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
How did Orchestra BioMed Holdings Inc (OBIO) fare last session? - uspostnews.com
Orchestra BioMed Secures FDA Clearance for Virtue Trial to Advance Coronary ISR Treatment - MyChesCo
Orchestra Biomed sees $149,201 stock purchase by RTW Investments By Investing.com - Investing.com Australia
Orchestra BioMed Holdings Inc [OBIO] Records 200-Day SMA of $5.25 - knoxdaily.com
Orchestra BioMed to Present at Jefferies Global Healthcare Conference - MyChesCo
Geode Capital Management LLC Boosts Stock Holdings in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) - Defense World
FDA approves head-to-head trial of Orchestra BioMed’s balloon - Investing.com
Orchestra BioMed (OBIO) Gains FDA Nod for Updated Coronary ISR T - GuruFocus
Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy - Diagnostic and Interventional Cardiology
FDA Clears Orchestra BioMed's Virtue SAB Trial To Treat Coronary ISR - Nasdaq
Orchestra BioMed Receives FDA Approval for IDE Amendment - TipRanks
Orchestra Biomed Receives FDA Approval Of Ide To Initiate U.S. Coronary Pivotal Trial Randomizing First-In-Class Sirolimus-Angioinfusion Balloon, Virtue Sab, Head-To-Head With Paclitaxel-Coated Balloon - marketscreener.com
Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon - The Manila Times
Orchestra BioMed's Revolutionary Sirolimus Balloon Gets FDA Green Light for Head-to-Head Trial - Stock Titan
FDA approves head-to-head trial of Orchestra BioMed’s balloon By Investing.com - Investing.com Canada
Orchestra BioMed (NASDAQ:OBIO) Shares Down 6.1% – Time to Sell? - Defense World
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences - GlobeNewswire
Orchestra BioMed Secures Triple Conference Lineup: CEO Sets Major Investor Presentations - Stock Titan
Analyzing PetVivo (NASDAQ:PETV) & Orchestra BioMed (NASDAQ:OBIO) - Defense World
1.54%
7.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):